Canine MHC-I genotyping and tumor specific neoantigen determination
Canine MHC-I genotyping and tumor specific neoantigen determination
批准号:
10220542
负责人:
William Hildebrand
金额:
$49.2万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-05-11 至 2026-04-30
关键词:
AddressAdvanced Malignant NeoplasmAlgorithmsAllelesBase PairingBehavior TherapyBindingCanis familiarisCell Culture TechniquesCell LineCellsClinicalClinical DataClinical TrialsCollaborationsCrystallizationDataData AnalysesData CommonsDatabasesDevelopmentEtiologyFundingGenomeGenotypeHeterogeneityHumanImmune systemInstitutesMajor Histocompatibility ComplexMalignant NeoplasmsMass Spectrum AnalysisMeasuresModelingMolecularNational Cancer InstituteNeural Network SimulationOncologyOutcomePeptidesPopulationPre-Clinical ModelProteinsPublishingQuality ControlResearchResourcesRodent ModelSamplingSequence Read ArchiveSoftware ToolsStructureTimeTrainingTranslatingTranslational ResearchTreatment outcomeVaccinationValidationWorkartificial neural networkcancer immunotherapycancer preventioncancer therapydata resourceexome sequencingexperiencegenome sequencinghuman genomicsimmunogenicityimmunotherapy trialsmutantneoantigensnext generation sequencingpre-clinicalpreventsoftware developmentsuccesstooltranscriptometranscriptome sequencingtranslational modeltumorwhole genome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Being naturally occurring and with an intact immune system, spontaneous cancers in pet dogs have the
potential to effectively bridge a current gap between preclinical models and human clinical trials, advancing
cancer immunotherapy. However, a current lack of essential resources creates roadblocks to the effective use
of canine cancers. The deficiency is clearly seen in predicting tumor-specific neoantigen (TSNA), attractive
targets in cancer treatment and prevention. TSNAs arise when intracellular mutant peptides, created by
cancer-associated somatic alterations, are presented by the cell’s histocompatibility complex class I (MHC-I)
molecules. Hence, MHC-I genotyping is a prerequisite for TSNA prediction. However, with few MHC-I alleles
known to date, MHC-I genotyping for the dog is a significant challenge. Moreover, because of the very limited
MHC-I protein crystal structures and experimental peptide binding data, there currently lack public tools to
predict TSNAs specifically for the dog, in contrast to the human with many tools developed.
With the next generation sequencing (NGS) data published for thousands of dogs from hundreds of breeds,
now is the time to address these deficiencies. We propose to combine our expertise, NGS data analysis by
the Zhao (PI) lab and MHC-I characterization by the Hildebrand (MPI) lab, to develop software tools and data
resources for large scale MHC-I genotyping and systematic TSNA prediction for the dog. We will also
genotype MHC-I alleles of thousands of dogs sequenced and predict TSNAs for hundreds of canine tumors
characterized. We will use our proposed MHC-I genotype and TSNA discovery tools to assist a NCI-funded
immunotherapy trial via collaboration with Dr. Steven Dow, and the Vaccination Against Canine Cancer Study
(VACCS) trial via collaboration with Dr. Douglas Thamm.
By establishing resources that are critically missing at present, our work will significantly enhance the
applicability of the dog model for translational research.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
rPIV5- and AVLP-vectored vaccine development with public tumor-specific neoantigens
-
批准号:10831315
-
项目类别:
-
资助金额:$14.67万
-
财政年份:2021
-
负责人:William Hildebrand
-
依托单位:
Canine MHC-I genotyping and tumor specific neoantigen determination
-
批准号:10404109
-
项目类别:
-
资助金额:$45.04万
-
财政年份:2021
-
负责人:William Hildebrand
-
依托单位:
Canine MHC-I genotyping and tumor specific neoantigen determination
-
批准号:10630913
-
项目类别:
-
资助金额:$46.27万
-
财政年份:2021
-
负责人:William Hildebrand
-
依托单位:
Human natural killer cell recognition of cytomegalovirus
-
批准号:8617610
-
项目类别:
-
资助金额:$20.35万
-
财政年份:2014
-
负责人:William Hildebrand
-
依托单位:
Direct Discovery of HLA-associated Influenza Epitopes
-
批准号:8481492
-
项目类别:
-
资助金额:$38.96万
-
财政年份:2012
-
负责人:William Hildebrand
-
依托单位:
Direct Discovery of HLA-associated Influenza Epitopes
-
批准号:8434472
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2012
-
负责人:William Hildebrand
-
依托单位:
Discovery and Targeting of HIV-1 Associated Antigens
-
批准号:8106378
-
项目类别:
-
资助金额:$50.98万
-
财政年份:2010
-
负责人:William Hildebrand
-
依托单位:
Discovery and Targeting of HIV-1 Associated Antigens
-
批准号:7984351
-
项目类别:
-
资助金额:$52.69万
-
财政年份:2010
-
负责人:William Hildebrand
-
依托单位:
Discovery and Targeting of HIV-1 Associated Antigens
-
批准号:8493984
-
项目类别:
-
资助金额:$47.92万
-
财政年份:2010
-
负责人:William Hildebrand
-
依托单位:
Discovery and Targeting of HIV-1 Associated Antigens
-
批准号:8288353
-
项目类别:
-
资助金额:$50.98万
-
财政年份:2010
-
负责人:William Hildebrand
-
依托单位:
Discovery and Targeting of West Nile Virus Epitopes
-
批准号:8069599
-
项目类别:
-
资助金额:$118.53万
-
财政年份:2009
-
负责人:William Hildebrand
-
依托单位:
Discovery and Targeting of West Nile Virus Epitopes
-
批准号:8245072
-
项目类别:
-
资助金额:$115.97万
-
财政年份:2009
-
负责人:William Hildebrand
-
依托单位:
Discovery and Targeting of West Nile Virus Epitopes
-
批准号:8459018
-
项目类别:
-
资助金额:$99.91万
-
财政年份:2009
-
负责人:William Hildebrand
-
依托单位:
Discovery and Targeting of West Nile Virus Epitopes
-
批准号:7644592
-
项目类别:
-
资助金额:$79.72万
-
财政年份:2009
-
负责人:William Hildebrand
-
依托单位:
Discovery and Targeting of West Nile Virus Epitopes
-
批准号:7800280
-
项目类别:
-
资助金额:$119.3万
-
财政年份:2009
-
负责人:William Hildebrand
-
依托单位:
Direct Epitope Identification and Validation
-
批准号:7930945
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2004
-
负责人:William Hildebrand
-
依托单位:
BAA-APPLICATION OF HLA DATA TO DEVELOP & IMPROVE VACCINE
-
批准号:6153530
-
项目类别:
-
资助金额:$35.06万
-
财政年份:1999
-
负责人:William Hildebrand
-
依托单位:
BAA-APPLICATION OF HLA DATA TO DEVELOP & IMPROVE VACCINE
-
批准号:6355490
-
项目类别:
-
资助金额:$36.04万
-
财政年份:1999
-
负责人:William Hildebrand
-
依托单位:
BAA-APPLICATION OF HLA DATA TO DEVELOP & IMPROVE VACCINE
-
批准号:6214440
-
项目类别:
-
资助金额:$0.0万
-
财政年份:1999
-
负责人:William Hildebrand
-
依托单位:
BAA-APPLICATION OF HLA DATA TO DEVELOP & IMPROVE VACCINE
-
批准号:6078695
-
项目类别:
-
资助金额:$36.29万
-
财政年份:1999
-
负责人:William Hildebrand
-
依托单位: